Knowing the Appropriateness of Running Noninferiority Trials in Oncology
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either.
Renal Cell Carcinoma
CheckMate 214: Long-Term Results Confirm Superiority of Nivolumab Plus Ipilimumab for mRCC
Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations.
Elevated NLR Combined With Low Sodium Predicts Worse Survival in RCC
At RCC diagnosis, patients with an neutrophil-lymphocyte ratio (NLR) above 3.0 and concomitant hyponatremia had a significant 2.8-fold increased risk of death compared with those who had an NLR of 3.0 or lower and normal sodium levels, a Danish study found.
Axitinib Did Not Meet Study End Point in mRCC, but Dosing Found Feasible
Although study failed to meet its primary endpoint, the researchers suggest approach could be used in clinical practice.
Tapping Into the Therapeutic Expertise of High-Volume Cancer Centers
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems.
Looking at Survival Differently in Patients With Metastatic Kidney Cancer
Conditional survival may more accurately assess prognosis than traditional survival for patients with metastatic kidney cancer, but the metric is not without its caveats.
Right-Sided RCC Predicts Better Outcomes in Patients With Larger Tumors
Among patients undergoing surgery for 10 cm or larger renal cell carcinoma tumors, right-sided tumors are independently associated with improved cancer-specific survival compared with left-sided tumors, a study found.
New Trial Attempts to Make Genetic Counseling and Testing More Accessible
The researchers wrote that “genetic counseling must be further explored to find an optimal balance of clinical quality with increased access and financial sustainability.”
T-Cell Cryopreservation for Use in Future Cancer Treatment: Hot or Hype?
Can healthy immune cells from a patient be frozen and used in the future to make adoptive cell therapies in the event of a cancer diagnosis?
Upfront Immune Checkpoint Inhibition Called New Metastatic RCC Standard of Care
Updated European Association of Urology guidelines recommend pembrolizumab plus axitinib or ipilimumab plus nivolumab for the first-line treatment of metastatic clear-cell renal cell carcinoma.
Next post in Renal Cell Carcinoma
